Real-world therapy sequencing in mPC

Episode 10. Alicia Morgans and Gunhild von Amsberg reflect on real-world challenges of sequencing therapies for mPC, including how HRR mutation type – especially BRCA1/2 – influences treatment choices and prognosis. They discuss when retesting is clinically justified and the complexities of interpreting multi-mutation reports. Von Amsberg shares insights from pivotal trials like TRITON and BRCAAway. The conversation centers on integrating real-world data (RWD) with clinical trial evidence, prioritizing actionable findings in multi-mutation reports, and supporting patients through shared decision-making and genetic counseling. View transcript.

Chapters
00:46 HRRm testing: Impact on therapy choices
03:30 How mutation type guides sequencing
05:36 Deciding on HRRm retesting
08:45 Integrating RWD into treatment choices
10:36 TRITON trial: Key clinical insights
12:48 BRCAAway trial: Combination therapies
14:51 Interpreting HRRm testing reports
16:58 How should HRR findings be prioritized?
19:56 Talking about HRR results with patients

Return to episode list

Meet the guest speaker

Gunhild von Amsberg, MD

Gunhild von Amsberg is Professor of Uro-Oncology in the Department of Hematology and Oncology at Martini-Klinik, Hamburg, Germany, and at the Center of Oncology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf. Her work focuses on systemic treatment strategies for advanced prostate cancer, urothelial carcinoma, and renal cell carcinoma. She is a member of the German S3 Guideline Committees for prostate, penile, and urothelial carcinoma and serves on the Independent Data Monitoring Committee of the Swiss Group for Clinical Cancer Research.

Disclosures: No disclosures provided at the time of publication.